The FASEB Journal, Vol 10, 1219-1226, Copyright © 1996 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia

V Hack, A Gross, R Kinscherf, M Bockstette, W Fiers, G Berke and W Droge
Division of Immunochemistry, Deutsches Krebsforschungszentrum, Heidelberg, Germany.

Excessive urea excretion associated with a negative nitrogen balance and massive loss of skeletal muscle mass (cachexia) is a frequent life threatening complication in malignancies and HIV infection. As these patients have often elevated interleukin-6 (IL-6) and abnormally low cystine levels, we have now determined the intracellular levels of glutathione and other cysteine derivatives in the liver and muscle tissue of IL-6-treated or tumor-bearing C57BL/6 mice. IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis. Treatment with cysteine, conversely, caused an increase in sulfate, glutamine/urea ratios, and glutamine/glutamate ratios and may thus be a useful therapeutic tool in clinical medicine. In contrast to the liver, muscle tissue of tumor-bearing mice showed decreased glutathione and increased sulfate levels, suggesting that the cysteine pool may be drained by an increased cysteine catabolism in this tissue. The findings indicate that tumor cachexia is triggered initially by IL-6 and is later sustained by processes driven by an abnormal cysteine metabolism in different organs.-Hack, V., Gross, A., Kinscherf, R., Bockstette, M., Fiers, W., Berke, G., and Droge, W. Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia.

This article has been cited by other articles:

				A. L. Theiss, T. S. Obertone, D. Merlin, and S. V. Sitaraman Interleukin-6 Transcriptionally Regulates Prohibitin Expression in Intestinal Epithelial Cells J. Biol. Chem., April 27, 2007; 282(17): 12804 - 12812. [Abstract] [Full Text] [PDF]

				G. Mantovani, C. Madeddu, A. Maccio, G. Gramignano, M. R. Lusso, E. Massa, G. Astara, and R. Serpe Cancer-Related Anorexia/Cachexia Syndrome and Oxidative Stress: An Innovative Approach beyond Current Treatment Cancer Epidemiol. Biomarkers Prev., October 1, 2004; 13(10): 1651 - 1659. [Abstract] [Full Text] [PDF]

				M. P. K. J. ENGELEN, A. M. W. J. SCHOLS, J. D. DOES, N. E. P. DEUTZ, and E. F. M. WOUTERS Altered Glutamate Metabolism Is Associated with Reduced Muscle Glutathione Levels in Patients with Emphysema Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 98 - 103. [Abstract] [Full Text]

				E. SCHMID, A. HOTZ-WAGENBLATT, V. HACK, and W. DRÖGE Phosphorylation of the insulin receptor kinase by phosphocreatine in combination with hydrogen peroxide: the structural basis of redox priming FASEB J, September 1, 1999; 13(12): 1491 - 1500. [Abstract] [Full Text]

				A. Ushmorov, V. Hack, and W. Droge Differential Reconstitution of Mitochondrial Respiratory Chain Activity and Plasma Redox State by Cysteine and Ornithine in a Model of Cancer Cachexia Cancer Res., July 1, 1999; 59(14): 3527 - 3534. [Abstract] [Full Text] [PDF]

				B Sido, V Hack, A Hochlehnert, H Lipps, C Herfarth, and W Droge Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease Gut, April 1, 1998; 42(4): 485 - 492. [Abstract] [Full Text] [PDF]

				A. Morales, C. Garcia-Ruiz, M. Miranda, M. Mari, A. Colell, E. Ardite, and J. C. Fernandez-Checa Tumor Necrosis Factor Increases Hepatocellular Glutathione by Transcriptional Regulation of the Heavy Subunit Chain of gamma -Glutamylcysteine Synthetase J. Biol. Chem., November 28, 1997; 272(48): 30371 - 30379. [Abstract] [Full Text] [PDF]